Gene therapy leaders aim to help more Baby KJs with novel regulatory models

Gene Therapy Leaders Advance Bespoke Treatments, Navigate Regulatory Hurdles

Cell and gene therapy leaders are discussing ways to accelerate bespoke gene editing treatments for children, exemplified by Baby KJ Muldoon's successful personalized CRISPR treatment for CPS1 deficiency. The FDA's plausible mechanism pathway aims to expedite therapies for ultra-rare diseases where randomized trials are unfeasible. However, its requirement for discrete applications per drug, rather than a process-level approach, led to EveryONE Medicines' closure due to perceived commercialization shortcomings. Despite these challenges, efforts continue, with the Innovative Genomics Institute planning a trial for familial hemophagocytic lymphohistiocytosis (HLH) using customized base editing RNAs, advocating for master clinical protocols for diseases with multiple genetic causes.

• The success of Baby KJ Muldoon's personalized CRISPR treatment for CPS1 deficiency has paved the way for further advancements in bespoke gene editing. The Innovative Genomics Institute is now preparing to initiate a trial at UCSF by the end of the year for a child with familial hemophagocytic lymphohistiocytosis (HLH), focusing on customized base editing RNAs to address this rare genetic disorder.
• The FDA's plausible mechanism pathway, designed to accelerate gene therapies for ultra-rare diseases, has faced criticism for its implementation. EveryONE Medicines ceased operations, citing the pathway's requirement for discrete applications per drug as a barrier to commercialization, contrasting it with the more flexible process-level approach seen in the U.K. pilot program.
• Beyond the plausible mechanism pathway, the FDA has introduced Platform Technology Designation to streamline reviews for drugs utilizing the same underlying technologies. Sarepta Therapeutics and Krystal Biotech have received such designations for their viral vectors, while there's a growing industry call for increased data sharing in cell and gene therapy to further accelerate development, particularly for pediatric rare diseases.

Why Current CPS1 Deficiency Treatments Fall Short

Current treatment approaches for CPS1 deficiency face significant challenges that limit their effectiveness, particularly in severe neonatal cases. Despite advances in therapeutic interventions, outcomes remain poor with high morbidity and mortality rates. The complexity of managing hyperammonemic crises, combined with the rarity of the condition, creates substantial barriers to developing evidence-based treatment protocols.

• Ineffectiveness of standard dialysis protocols - Current dialysis practice effectively clears ammonia but shows no impact on patient outcomes, with total mortality remaining at 25% and only 20% of patients achieving normal developmental outcomes

• Uncertainty in treatment thresholds - The currently defined ammonia threshold of 500 μmol/L to initiate dialysis has unknown utility for improving clinical outcomes, with mean ammonia levels triggering dialysis reaching 1199 μmol/L

• Prevention challenges in neonatal cases - Hyperammonemia remains difficult to prevent even when treatment is started prospectively due to an affected relative, indicating fundamental limitations in current preventive approaches

• Limited neuroprotective options - Therapeutic hypothermia has been reported only three times with limited experience precluding accurate safety and efficacy conclusions, and cooling protocols required discontinuation in 75% of cases due to complications like hypotension and hemorrhage

• Insufficient evidence base - Clinical studies are extremely difficult to conduct due to disease rarity, resulting in scant high-level evidence that is insufficient for developing robust clinical guidelines

• Diagnostic delays in adult-onset cases - Comorbid conditions and physical trauma frequently delay recognition of underlying urea cycle defects when they present during environmental stress or critical illness

Personalized CRISPR's Expanding Role Beyond CPS1

Personalized CRISPR therapies are being investigated across a diverse range of genetic and acquired diseases beyond CPS1 deficiency. Current research encompasses hematologic disorders, metabolic diseases, autoimmune conditions, and various genetic syndromes, with intervention models ranging from ex vivo cell editing to in vivo delivery approaches.

How CPS1 Deficiency Treatment is Evolving

Recent clinical data demonstrates significant evolution in CPS1 deficiency treatment, with several breakthrough therapeutic approaches emerging alongside refined standard care protocols. The most notable advancement is hepatocyte-like cell (HLC) infusion therapy derived from human embryonic stem cells, which has shown remarkable success as bridging therapy for neonatal-onset cases. In a 2025 clinical trial involving five neonates with urea cycle disorders, all patients who received HLC infusions exceeded the target weight of 6 kg while maintaining metabolic stability and successfully bridged to transplantation. Post-transplantation follow-up revealed stable growth, metabolic control, and no neurological complications, with preclinical studies confirming that HLCs successfully engrafted in the liver without adverse migration or tumor formation.

Gene therapy represents another transformative development, with AAV8.CPS1 vector therapy showing promising results in preclinical studies. Long-term survival extending to 9 months was achieved in treated Cps1-deficient mice, with ammonia control maintained throughout the study period while all control animals died from marked hyperammonemia. Additionally, the transition from sodium benzoate to glycerol phenylbutyrate has gained momentum, with a 2025 study of eight pediatric patients demonstrating that direct replacement maintained metabolic control while offering improved palatability and reduced dosing volume. Pre-transition mean ammonia levels of 37 μmol/L decreased to 29 μmol/L post-transition, with no related adverse drug reactions reported.

Real-world clinical outcomes from major treatment centers provide additional insights into evolving treatment paradigms. Data from Peking University First Hospital covering 2014-2023 showed that among seven CPS1 deficiency patients, early-onset cases required aggressive intervention including liver transplantation at 4 months combined with sodium phenylbutyrate and N-carbamoyl-L-glutamate to achieve favorable outcomes. Meanwhile, refinements in acute management protocols have emphasized the critical role of continuous renal replacement therapy in preventing rebound hyperammonemia, along with intracranial pressure monitoring and targeted cerebral edema management using 3% hypertonic saline and temperature control. These advances collectively represent a shift toward more sophisticated, personalized treatment approaches that address both acute metabolic crises and long-term disease management.

Accelerating Bespoke Gene Editing for Ultra-Rare Diseases

The remarkable success of personalized CRISPR treatment for Baby KJ Muldoon, addressing a life-threatening CPS1 deficiency, vividly illustrates the transformative potential of gene editing in pediatric medicine. This breakthrough, alongside ongoing advancements in CRISPR-Cas and base editing technologies, particularly for hematopoietic stem cells, is ushering in an era where previously incurable genetic disorders, from arginase deficiency to familial hemophagocytic lymphohistiocytosis (HLH), could see curative interventions. The scientific community is rapidly developing precise tools to correct pathogenic mutations, offering hope for millions affected by rare diseases globally.

However, translating this scientific promise into widespread clinical reality presents a complex set of challenges. While the FDA has introduced pathways like the "plausible mechanism" to expedite therapies for ultra-rare conditions, its current requirement for discrete applications per drug, rather than a more adaptable process-level approach, creates significant hurdles. This regulatory rigidity, coupled with the substantial financial investment required—clinical-stage R&D for cell and gene therapies is estimated at nearly $2 billion per asset—can deter commercial interest and lead to market failures, as seen with EveryONE Medicines.

To truly unlock the potential of bespoke gene editing, a strategic evolution is necessary. This includes:

• Advocating for flexible regulatory frameworks: The adoption of master clinical protocols, especially for diseases with multiple genetic causes, could streamline development and approval, fostering innovation.

• Developing sustainable commercial models: Companies must innovate beyond traditional paradigms to manage high costs and small patient populations, ensuring these life-changing therapies reach those who need them.

• Prioritizing long-term safety and efficacy data: Continuous monitoring and robust post-market surveillance are crucial to build confidence and address concerns regarding potential off-target effects or long-term risks, which are still being understood for many novel gene therapies.

The future of precision medicine for rare diseases hinges on a collaborative effort between innovators, regulators, and payers to create an ecosystem that supports both groundbreaking science and equitable patient access.